Found: 5
Select item for more details and to access through your institution.
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1810, doi. 10.1111/dom.14767
- By:
- Publication type:
- Article
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 899, doi. 10.1111/dom.14650
- By:
- Publication type:
- Article
Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 7, p. 1631, doi. 10.1111/dom.14383
- By:
- Publication type:
- Article
184-OR: Liver Fibrosis Scores Do Not Predict Response to Therapy in T2DM.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-184-OR
- By:
- Publication type:
- Article
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
- Published in:
- 2021
- By:
- Publication type:
- journal article